Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

Abstract Learning Objectives After completing this course, the reader will be able to: List at
least four local hemostatic agents and dressings for controlling localized bleeding in a …

Thrombocytopenia is a frequent complication of cancer and its treatment. The causes of
thrombocytopenia in cancer patients can be diverse and multifactorial. Systemic …

Background Antifibrinolytic agents such as tranexamic acid (TXA) are commonly used as
adjunctive therapies to prevent and treat excessive bleeding. In non-surgical settings, TXA is …

Background People with haematological disorders are frequently at risk of severe or life‐
threatening bleeding as a result of thrombocytopenia (reduced platelet count). This is …

Background Bleeding in endoscopic sinus surgery (ESS) may increase the risk of
intraoperative complications and is associated with poorer outcomes Antifibrinolytic agents …

Patients with acute leukemia frequently develop thrombocytopenia and hemostatic
complications caused by coagulopathy. Coagulopathy complicates the management of …

Cancer patients have varying incidence, depth and duration of thrombocytopenia. The
mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is …